PATIENT‐REPORTED OUTCOMES (PROs) IN WALDENSTRÖM MACROGLOBULINEMIA (WM) PATIENTS TREATED WITH IBRUTINIB‐RITUXIMAB IN THE INNOVATE STUDY. (12th June 2019) - Tedeschi, A.; Dimopoulos, M.A.; Trotman, J.; García‐Sanz, R.; Macdonald, D.; Mahe, B.; Herbaux, C.; Heffner, L.T.; Tam, C.S.; Varettoni, M.; Palomba, M.L.; Matous, J.V.; et al.